Palmitoyl Tripeptide-1

A lipopeptide consisting of the GHK (Gly-His-Lys) sequence attached to a palmitoyl fatty acid chain. It mimics the body's own collagen-repair signaling by acting as a matrikine — a fragment of extracellular matrix proteins that signals fibroblasts to produce new collagen. Often combined with Palmitoyl Tetrapeptide-7 in commercial formulations (marketed as Matrixyl 3000).

• GHK sequence acts as a matrikine, mimicking collagen degradation fragments
• Activates TGF-beta signaling to upregulate collagen gene transcription
• Palmitoyl group enhances stratum corneum penetration for improved dermal delivery
• Stimulates fibroblast proliferation and glycosaminoglycan synthesis
• Synergizes with anti-inflammatory peptides to reduce inflammaging

• Known allergy to any component
• Severely compromised skin barrier (open wounds, active infections)

Store topical formulations at room temperature (15–25°C (59–77°F)) away from sunlight. Concentrated solutions: keep at 2–8°C (36–46°F). Stable for 12-24 months in properly formulated products.

Palmitoyl Tripeptide-1 was developed as a biomimetic signaling peptide based on the naturally occurring GHK sequence. In vitro studies demonstrated significant upregulation of collagen I and III synthesis in human dermal fibroblasts. When combined with Palmitoyl Tetrapeptide-7 (as Matrixyl 3000, developed by Sederma), clinical studies showed synergistic wrinkle reduction superior to either peptide alone. A 12-week study demonstrated up to 44% reduction in wrinkle volume. It is widely incorporated in premium anti-aging skincare products.